Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The validity and sensitivity of PANSS‐6 in treatment‐resistant schizophrenia
Søren Dinesen Østergaard, Leslie Foldager, Ole Mors, et al.
Acta Psychiatrica Scandinavica (2018) Vol. 138, Iss. 5, pp. 420-431
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
Christoph U. Correll, Ofer Agid, Benedicto Crespo‐Facorro, et al.
CNS Drugs (2022) Vol. 36, Iss. 7, pp. 659-679
Open Access | Times Cited: 98
COSMIN systematic review and meta-analysis of the measurement properties of the PANSS-6
Simon Geck, Maximilian Roithmeier, Markus Bühner, et al.
European Neuropsychopharmacology (2025) Vol. 94, pp. 41-50
Open Access | Times Cited: 2
Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia
Débora Luciana Melzer-Ribeiro, Isabel Cristina Napolitano, Sónia Leite, et al.
Schizophrenia Research (2023) Vol. 268, pp. 252-260
Closed Access | Times Cited: 15
COSMIN review of the PANSS Marder factor solution and other factor models in people with schizophrenia
Maximilian Roithmeier, Simon Geck, Markus Bühner, et al.
Schizophrenia (2025) Vol. 11, Iss. 1
Open Access
Comparing PANSS-6 and PANSS-30 for clinical and functional outcomes in first-episode psychosis: A 2-year follow-up in a Spanish cohort
Vicent Llorca-Bofí, Marina Garriga, Gisela Mezquida, et al.
European Neuropsychopharmacology (2025) Vol. 95, pp. 9-13
Closed Access
COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS)
Simon Geck, Maximilian Roithmeier, Markus Bühner, et al.
EClinicalMedicine (2025) Vol. 82, pp. 103155-103155
Open Access
Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials
Fredrik Hieronymus, Christoph U. Correll, Søren Dinesen Østergaard
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Catalase and interleukin-6 serum elevation in a prediction of treatment-resistance in male schizophrenia patients
Haidong Yang, Jing Zhang, Man Yang, et al.
Asian Journal of Psychiatry (2022) Vol. 79, pp. 103400-103400
Open Access | Times Cited: 12
Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study
Rosana Freitas, Bernardo dos Santos, Carlo Altamura, et al.
Psychiatry Research (2019) Vol. 276, pp. 210-217
Open Access | Times Cited: 18
<p>Transdermal Asenapine in Schizophrenia: A Systematic Review</p>
Brennan Carrithers, Rif S. El‐Mallakh
Patient Preference and Adherence (2020) Vol. Volume 14, pp. 1541-1551
Open Access | Times Cited: 18
Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview
Pernille Kølbæk, David E. Dines, Tine Holm, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 9, pp. 1081-1090
Closed Access | Times Cited: 15
Scalability of the Positive and Negative Syndrome Scale in first‐episode schizophrenia assessed by Rasch models
Lone Baandrup, Peter Allerup, Mette Ødegaard Nielsen, et al.
Acta Psychiatrica Scandinavica (2022) Vol. 146, Iss. 1, pp. 21-35
Open Access | Times Cited: 11
Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
Fredrik Hieronymus, Pernille Kølbæk, Christoph U. Correll, et al.
Schizophrenia (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 12
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia
Cecilie Marie Nielsen, Pernille Kølbæk, David E. Dines, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 11, pp. 1208-1217
Closed Access | Times Cited: 9
Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes
Naista Zhand, David Attwood, Alain Labelle, et al.
Contemporary Clinical Trials Communications (2024) Vol. 41, pp. 101337-101337
Open Access | Times Cited: 1
Clinical validation of the Symptom Self-rating Scale for Schizophrenia (4S) among inpatients
Pernille Kølbæk, Daniel Guinart, Mark Opler, et al.
Nordic Journal of Psychiatry (2021) Vol. 75, Iss. 6, pp. 454-464
Closed Access | Times Cited: 8
Measurement based care in schizophrenia—Feasibility in routine clinical practice
Damodharan Dinakaran, Vanteemar S. Sreeraj, Ganesan Venkatasubramanian
Asian Journal of Psychiatry (2020) Vol. 49, pp. 101954-101954
Closed Access | Times Cited: 7
Measuring progress in measurement‐based care with smartphone tools
John Torous
Acta Psychiatrica Scandinavica (2019) Vol. 140, Iss. 4, pp. 293-294
Open Access | Times Cited: 5
ECT versus Sham for clozapine-resistant schizophrenia: A secondary analysis of a pilot study based on PANSS-30 individual items
Débora Luciana Melzer-Ribeiro, Maria Cristina R. Grilli-Tissot, Hélio Elkis
Brain stimulation (2020) Vol. 13, Iss. 6, pp. 1517-1518
Open Access | Times Cited: 4
Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6)
Pernille Kølbæk, David E. Dines, Johanna Hansen, et al.
Schizophrenia Research (2021) Vol. 228, pp. 438-446
Closed Access | Times Cited: 4
Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia
Wenxi Sun, Tingting Jin, Haidong Yang, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access
Variations to plasma H2O2 levels and TAC in chronical medicated and treatment-resistant male schizophrenia patients: Correlations with psychopathology
Haidong Yang, Wenxi Sun, Man Yang, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access
Medication burden reduction and early clinical benefit through aripiprazole once monthly in schizophrenia patients with polypharmacy
Jiwan Moon, Hyeryun Yang, Sra Jung, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 135, pp. 111115-111115
Closed Access
The Transdiagnostic Global Impression - Psychopathology scale (TGI-P): Initial development of a novel transdiagnostic tool for assessing, tracking, and visualising psychiatric symptom severity in everyday practice
Christoph U. Correll, Z.B. Dombi, Ágota Barabássy, et al.
European Neuropsychopharmacology (2024) Vol. 88, pp. 31-39
Open Access
Are informants required to obtain valid ratings on the Positive and Negative Syndrome Scale (PANSS)?
Cecilie Marie Nielsen, Pernille Kølbæk, David E. Dines, et al.
Schizophrenia (2023) Vol. 9, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top